29.05.2013 - AstraZeneca has filled its pipeline with a Phase III fish oil cardioprotective drug, taking over Omthera Pharmaceuticals for $443m.
The British-Swedish drug giant will pay Omthera $12.70 per share, or approximately $323 million, a premium of 88% to Omthera's closing price on Friday. In addition, Omthera shareholders will get "contingent value rights" (CVRs) of up to approximately $4.70 per share, or $120 million in total, depending on the success of Omthera's experimental fish oil-derived medicine Epanova to treat patients with very high triglyceride levels. Epanova is a mixture of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
The expansion into the cardiovascular market pitches AstraZeneca into competition with rivals including Irish Amarin, British Glaxo SmithKline that is marketing the $917m fish-oil derived medicine Lovaza or Geman BASF, who has taken over Norwegian Pronova. Omthera's drug is ready to be filed for US approval and could be combined with AstraZeneca's cholesterol fighter Crestor.
25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.
21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.
11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.